Search

Your search keyword '"Cho, Eun Kyung"' showing total 337 results

Search Constraints

Start Over You searched for: Author "Cho, Eun Kyung" Remove constraint Author: "Cho, Eun Kyung" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
337 results on '"Cho, Eun Kyung"'

Search Results

1. The forb-flex method for odd coloring and proper conflict-free coloring of planar graphs

2. On the interval coloring impropriety of graphs

3. Domination of subcubic planar graphs with large girth

5. Independent domination versus packing in subcubic graphs

7. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

8. Brooks-type theorems for relaxations of square colorings

9. Relaxation of Wegner's Planar Graph Conjecture for maximum degree 4

10. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

13. Proper conflict-free coloring of sparse graphs

14. Odd coloring of sparse graphs and planar graphs

15. Independent domination of graphs with bounded maximum degree

16. Tight bound for independent domination of cubic graphs without $4$-cycles

17. On independent domination of regular graphs

18. Improvements on Hippchen's Conjecture

19. Decomposing planar graphs into graphs with degree restrictions

20. The strong clique number of graphs with forbidden cycles

21. Partitioning planar graphs without $4$-cycles and $5$-cycles into bounded degree forests

22. Generalized list colouring of graphs

24. On induced saturation for paths

26. Sharp conditions for the existence of an even $[a,b]$-factor in a graph

27. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

29. A spectral characterisation of t-designs and its applications

30. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

33. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

34. Ginsenoside Rg3 restores hepatitis C virus–induced aberrant mitochondrial dynamics and inhibits virus propagation

37. Independent domination versus packing in subcubic graphs.

38. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

39. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

41. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

42. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

43. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

46. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer...

47. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

49. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Catalog

Books, media, physical & digital resources